Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Dennis Chin Lun Huang"'
Autor:
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lun Huang, Agnieszka Cseh, Keunchil Park, Yi-Long Wu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundAfatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of
Externí odkaz:
https://doaj.org/article/9f20422dd14b455088226a15dd90831a
Autor:
Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, Zhiyi Xue, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Yi-Long Wu, Jie Wang
Publikováno v:
Future Oncology. 18:1485-1497
Aim: To explore the relationship between mutations in cfDNA and response to afatinib. Patients & methods: In total, 64 patients from one Chinese site with locally advanced/metastatic EGFRm+ non-small-cell lung cancer, who received afatinib 40 mg once
Autor:
Jianhua Chen, Hairui Hua, Yun Fan, Yongqian Shu, Chengzhi Zhou, Dennis Chin-Lun Huang, Jacky Zhang, Caicun Zhou, Huijuan Wang
Publikováno v:
Lung Cancer. 147:209-213
Despite 1-4 % of NSCLC tumors harboring mutations in the HER2 gene, there are no approved HER2-pathway-targeted treatments available. We report an open-label, single-arm, multicenter phase II study investigating the efficacy and safety of afatinib in
Autor:
Hiroji Iwata, Molly C. Hardebeck, Anthony Gonçalves, Javier Garcia-Corbacho, Mingchi Hsu, Patricia LoRusso, Marta Puig, Mafalda Oliveira, Douglas Yee, Marie Paule Sablin, Aleix Prat, Dennis Chin-Lun Huang
Publikováno v:
Cancer Research. 80:P3-11
Background: Insulin-like growth factor receptor-1 (IGF-1R) signaling is implicated in cancer progression, prognosis, and treatment resistance. Cross-talk between IGF-1R signaling and cyclin-dependent kinase (CDK) 4 & 6 was reported in preclinical stu
Autor:
Seock-Ah Im, Patrick Neven, John Crown, Rosa-Maria Espadero, Noelia Martínez, Yen-Shen Lu, Jonas Bergh, Thomas Bogenrieder, J. Alejandro Pérez-Fidalgo, Peter Schmid, Guy Jerusalem, Laura Schlieker, Serafin Morales, Dennis Chin-Lun Huang, Douglas Adamson, Javier Cortes, Anthony Gonçalves, Keun Seok Lee, Marie-Paule Sablin, Aleix Prat
Publikováno v:
Breast Cancer Research
Breast Cancer Research, 2021, 23 (1), pp.8. ⟨10.1186/s13058-020-01382-8⟩
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Breast Cancer Research : BCR
Scientia
Breast Cancer Research, 2021, 23 (1), pp.8. ⟨10.1186/s13058-020-01382-8⟩
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Breast Cancer Research : BCR
Scientia
Background Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus everolimus a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fb312f1fe2cc964111c140ba48f774
https://hal.science/hal-03630009
https://hal.science/hal-03630009
Autor:
Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B. J. Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou, Yi-Long Wu
Publikováno v:
Targeted Oncology
Background Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) in randomized controlled trials. However, patients treated in real-world clini
Autor:
Jun Zhao, B J Srinivasa, Hai-Yan Tu, Konstantin Laktionov, Filippo de Marinis, Tejaswini Jalikop, Jifeng Feng, Eng Huat Tan, Victor C. S. Lee, Cheng-Ta Yang, Dariusz M. Kowalski, Maya Gottfried, Yi-Long Wu, Artem Poltoratskiy, Dennis Chin-Lun Huang, Agnieszka Cseh, Keunchil Park, L. Clementi, Antonio Passaro
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundAfatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of
Autor:
Rainer Georg Goeldner, Li-Tzong Chen, Alan Anthoney, Karim Rihawi, Ann-Lii Cheng, Maria Jove, Susanne Buschke, Jesus Corral, Vasiliki Michalarea, Jih-Hsiang Lee, Thomas Bogenrieder, Her Shyong Shiah, René Fuertig, Michael Ong, Ulrike Schmid, Chia-Chi Lin, Dennis Chin-Lun Huang, Chih-Hung Hsu, Johann S. de Bono, James Chih-Hsin Yang, Chia Jui Yen, Chris Twelves, Natalja Strelkowa
Publikováno v:
British Journal of Cancer
Background Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling. Two first-in-human trials assessed the maximum-tolerated/relevant biological dose (MTD/RBD)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a29e29df9b254be8f87f8fcc43c3fad
Autor:
Mingchi Hsu, Takashi Seto, Daniel Shao Weng Tan, Sang-We Kim, Chin-Chou Wang, Helen Hayoun Jung, Ki Hyeong Lee, Keunchil Park, Dennis Chin-Lun Huang, Wu Chou Su, Chia-Chi Lin, Byoung Chul Cho, Thomas Bogenrieder
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 2, Iss 9, Pp 100206-(2021)
JTO Clinical and Research Reports, Vol 2, Iss 9, Pp 100206-(2021)
Introduction Insulin-like growth factor signaling has been implicated in acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. This phase 1 trial (NCT02191891) investigated the combination of xentuzumab (an insulin-like growth facto
Autor:
Hua Bai, Dennis Chin-Lun Huang, Jiping Zhao, Huiying Chen, S. Meng, Jianchun Duan, Y-L. Wu, J. Wang, Xiuqin Wang, Y. Wang, Y. Tian
Publikováno v:
Annals of Oncology. 30:ix153-ix154
Background Afatinib has demonstrated efficacy and safety in pts with EGFRm+ NSCLC. We report a biomarker analysis of EGFR TKI-naive pts with EGFRm+ NSCLC treated with afatinib in a Phase IIIb study. The analysis explored the effect of tumor mutation